Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Purpose

This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with CMT1 and CMTX, to be conducted in two parts. Part 1 is non-randomized, open-label, dose-escalation and Part 2 is randomized, double-blind, and placebo-controlled. Visit ClinicalTrials.gov for more details. 

Procedures

  • Drug: ACE-083

For study details, please contact Amanda Cowsert:

Eligibility 

  • 18 years and older
  • Left and right ankle dorsiflexion Medical Research Council (MRC) manual muscle testing (MMT) grade 4- to 4+, inclusive
  • Females of childbearing potential must have negative urine pregnancy test prior to enrollment and use highly effective birth control methods during study participation and for 8 weeks following the last dose of ACE-083. Males must agree to use a condom during any sexual contact with females of childbearing potential while participating in the study and for 8 weeks following the last dose of ACE-083, even if he has undergone a successful vasectomy.
  • Ability to adhere to the study visit schedule/procedures, and to understand and comply with protocol requirements
  • Phase 1 and Phase 2 have specific eligibility requirements, contact the study team for more details

Additional criteria apply, please contact Amanda Cowsert:

Age

18 to 65
65 and over

Gender

Male
Female

Can be done from home

No

Keywords

Charcot-Marie Tooth, Charcot-Marie-Tooth disease, Neurology

Principal Investigator

S.H. Subramony, MD

Department

Neurology

Contact Information

amanda.cowsert@neurology.ufl.edu

352-294-8778


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at CTSI-Studies-L@lists.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams